Literature DB >> 12505281

Epidemiology of hepatocellular carcinoma.

Michael C Kew1.   

Abstract

Because of its high incidence in many of the most populous countries in the world, its often fulminant course, poor response to conservative treatment, low resectabilty rate when symptomatic, high recurrence rate after resection and liver transplantation, and grave prognosis, hepatocellular carcinoma is now regarded as one of the major malignant diseases. Hepatocellular carcinoma is the most common primary malignant tumour of the liver. Relative to other tumours, it ranks fifth in overall frequency (fifth in men and eighth in women) and fourth in annual mortality rate. An estimated 372,000 new cases of hepatocellular carcinoma are diagnosed each year, constituting 4.6% of all new human cancers (6.3% in men; 2.7% in women). The annual mortality rate from the tumour is virtually the same as its annual incidence. The highest incidences occur in eastern and southeastern Asia, some of the Western Pacific islands, and sub-Saharan Africa. Intermediate incidences are found in eastern and southern Europe, the Caribbean, Central America, and Western Asia. Hepatocellular carcinoma is uncommon in the remaining countries. Men are affected more often than are women. The incidence generally increases with increasing age, although there is a definite shift towards a younger age distribution in black African and ethnic Chinese populations.

Entities:  

Mesh:

Year:  2002        PMID: 12505281     DOI: 10.1016/s0300-483x(02)00251-2

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  37 in total

1.  Decreased aquaporin expression leads to increased resistance to apoptosis in hepatocellular carcinoma.

Authors:  Elizabeth M Jablonski; M Adrian Mattocks; Eugene Sokolov; Leonidas G Koniaris; Francis M Hughes; Nelson Fausto; Robert H Pierce; Iain H McKillop
Journal:  Cancer Lett       Date:  2006-11-03       Impact factor: 8.679

2.  Orthotopic liver transplantation as a rescue operation for recurrent hepatocellular carcinoma after partial hepatectomy.

Authors:  Zhuo Shao; Rocio Lopez; Bo Shen; Guang-Shun Yang
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

3.  Nanocomposite Carriers for Transarterial Chemoembolization of Liver Cancer.

Authors:  Dong-Hyun Kim; Andrew C Larson
Journal:  Interv Oncol 360       Date:  2016-11-17

4.  Preliminary study of apparent diffusion coefficient assessment after ion beam therapy for hepatocellular carcinoma.

Authors:  Masayuki Kanamoto; Tosiaki Miyati; Kazuki Terashima; Daisaku Suga; Nobukazu Fuwa
Journal:  Radiol Phys Technol       Date:  2016-04-07

5.  Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma.

Authors:  Dingxin Wang; Brian Jin; Robert J Lewandowski; Robert K Ryu; Kent T Sato; Mary F Mulcahy; Laura M Kulik; Frank H Miller; Riad Salem; Debiao Li; Reed A Omary; Andrew C Larson
Journal:  J Magn Reson Imaging       Date:  2010-05       Impact factor: 4.813

6.  Aberrant CpG island hypermethylation and down-regulation of Oct-6 mRNA expression in human hepatocellular carcinoma.

Authors:  Jing-Zhe Sun; Xue-Xi Yang; Xiang-Hong Li; Wei-Wen Xu; Ying Wang; Wei Zhu; Ming Li
Journal:  Dig Dis Sci       Date:  2011-03-30       Impact factor: 3.199

7.  Pulmonary resection for non-small cell lung cancer in patients with hepatocellular carcinoma.

Authors:  Takashi Iwata; Noritoshi Nishiyama; Koshi Nagano; Nobuhiro Izumi; Shinjiro Mizuguchi; Ryuhei Morita; Takuma Tsukioka; Shoji Hanada; Kiyotoshi Inoue; Shoji Kubo; Shigekazu Takemura; Shigefumi Suehiro
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

Review 8.  Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma.

Authors:  Yasunobu Matsuda
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

9.  Growth arrest and apoptosis of human hepatocellular carcinoma cells induced by hexamethylene bisacetamide.

Authors:  Gao-Liang Ouyang; Qiu-Feng Cai; Min Liu; Rui-Chuan Chen; Zhi Huang; Rui-Sheng Jiang; Fu Chen; Shui-Gen Hong; Shi-Deng Bao
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

10.  Effect of in vivo loss of GDF-15 on hepatocellular carcinogenesis.

Authors:  Teresa A Zimmers; Xiaoling Jin; Juan C Gutierrez; Cary Acosta; Iain H McKillop; Robert H Pierce; Leonidas G Koniaris
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-22       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.